1. Home
  2. INM vs GRI Comparison

INM vs GRI Comparison

Compare INM & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INM
  • GRI
  • Stock Information
  • Founded
  • INM 1981
  • GRI 2018
  • Country
  • INM Canada
  • GRI United States
  • Employees
  • INM N/A
  • GRI N/A
  • Industry
  • INM Biotechnology: Pharmaceutical Preparations
  • GRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • INM Health Care
  • GRI Health Care
  • Exchange
  • INM Nasdaq
  • GRI Nasdaq
  • Market Cap
  • INM 3.2M
  • GRI 3.4M
  • IPO Year
  • INM N/A
  • GRI N/A
  • Fundamental
  • Price
  • INM $2.31
  • GRI $1.29
  • Analyst Decision
  • INM
  • GRI Strong Buy
  • Analyst Count
  • INM 0
  • GRI 2
  • Target Price
  • INM N/A
  • GRI $22.00
  • AVG Volume (30 Days)
  • INM 145.5K
  • GRI 282.8K
  • Earning Date
  • INM 09-29-2025
  • GRI 08-13-2025
  • Dividend Yield
  • INM N/A
  • GRI N/A
  • EPS Growth
  • INM N/A
  • GRI N/A
  • EPS
  • INM N/A
  • GRI N/A
  • Revenue
  • INM $4,920,990.00
  • GRI N/A
  • Revenue This Year
  • INM N/A
  • GRI N/A
  • Revenue Next Year
  • INM N/A
  • GRI N/A
  • P/E Ratio
  • INM N/A
  • GRI N/A
  • Revenue Growth
  • INM N/A
  • GRI N/A
  • 52 Week Low
  • INM $1.72
  • GRI $1.10
  • 52 Week High
  • INM $15.70
  • GRI $30.43
  • Technical
  • Relative Strength Index (RSI)
  • INM 36.26
  • GRI 37.76
  • Support Level
  • INM $2.31
  • GRI $1.21
  • Resistance Level
  • INM $2.71
  • GRI $2.20
  • Average True Range (ATR)
  • INM 0.10
  • GRI 0.18
  • MACD
  • INM -0.04
  • GRI -0.10
  • Stochastic Oscillator
  • INM 2.22
  • GRI 8.11

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: